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Background: DUSP3 phosphatase, also known as Vaccinia-H1 Related (VHR) phosphatase, encoded by DUSP3/
Dusp3 gene, is a relatively small member of the dual-specificity protein phosphatases. In vitro studies showed that
DUSP3 is a negative regulator of ERK and JNK pathways in several cell lines. On the other hand, DUSP3 is implicated
in human cancer. It has been alternatively described as having tumor suppressive and oncogenic properties. Thus,
the available data suggest that DUSP3 plays complex and contradictory roles in tumorigenesis that could be cell
type-dependent. Since most of these studies were performed using recombinant proteins or in cell-transfection
based assays, the physiological function of DUSP3 has remained elusive.
Results: Using immunohistochemistry on human cervical sections, we observed a strong expression of DUSP3 in
endothelial cells (EC) suggesting a contribution for this phosphatase to EC functions. DUSP3 downregulation, using
RNA interference, in human EC reduced significantly in vitro tube formation on Matrigel and spheroid angiogenic
sprouting. However, this defect was not associated with an altered phosphorylation of the documented in vitro
DUSP3 substrates, ERK1/2, JNK1/2 and EGFR but was associated with an increased PKC phosphorylation. To
investigate the physiological function of DUSP3, we generated Dusp3-deficient mice by homologous
recombination. The obtained DUSP3−/− mice were healthy, fertile, with no spontaneous phenotype and no vascular
defect. However, DUSP3 deficiency prevented neo-vascularization of transplanted b-FGF containing Matrigel and
LLC xenograft tumors as evidenced by hemoglobin (Hb) and FITC-dextran quantifications. Furthermore, we found
that DUSP3 is required for b-FGF-induced microvessel outgrowth in the aortic ring assay.
Conclusions: All together, our data identify DUSP3 as a new important player in angiogenesis.
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The human genome harbors 104 genes encoding for
cysteine-based (Cys-based) phosphatases classified into
three classes on the basis of their amino acid sequences
and catalytic domains [1]. Dual-specificity phosphatases
(DUSPs) or Vaccinia-H1-like (VH1-Like) enzymes repre-
sent the largest group of class I of Cys-based motif phos-
phatases and is represented by 61 members with diverse
substrates specificity ranging from mRNA to inositol
phospholipids, p-Ser/p-Thr and p-Tyr. Among these 61* Correspondence: srahmouni@ulg.ac.be
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unless otherwise stated.phosphatases, 11 are specific for the MAPKs ERK, JNK
and p38 and are known as the typical DUSPs or MAPK
specific phosphatases (MKPs). The second group of the
VH1-like phosphatases is known as the atypical DUSPs
(A-DUSPs) represented by 19 small enzymes (with less
than 250aa) and are poorly characterized (reviewed in
[2]). Considering the important role of MAPKs in the
regulation of different cellular functions and their in-
volvement in different human diseases including cancer
[3-5], the activation as well as inhibition processes of
these serine/threonine kinase family has been well char-
acterized. Therefore, among all DUSPs, the MKPs have
been the most characterized in vitro and in vivo. TheLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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group is altered in human cancer (reviewed in [6]).
DUSP3, also called Vaccinia H1-Related (VHR), is
the founding member of the dual-specificity protein
phosphatases group. It consists of a 185 amino acids
(Mr 21 kDa) catalytic domain but no apparent targeting
domain or docking site and is encoded by DUSP3/Dusp3
gene [7]. The crystal structure of DUSP3 has been solved
and shows a shallow active site allowing DUSP3 to act on
both pTyr and pThr in its substrates [8]. DUSP3 has been
reported to dephosphorylate the MAPKs ERK and JNK,
but not p38 [7-9]. More recently, EGFR and ErbB2 were
reported as direct new substrates for this phosphatase in a
non-small cell lung cancer cell line NSCLC [10]. Unlike
many other MKPs, DUSP3 expression is not induced in
response to activation of MAPKs, but is regulated during
cell cycle progression [11,12]. In a previous study, we have
shown that in HeLa cells, the knockdown of endogenous
DUSP3 using RNA interference induces cell cycle arrest at
G1/S and G2/M phases and is accompanied by the hyper-
activation of ERK1/2 and JNK1/2 [11,12]. In line with this
finding, DUSP3 was found up-regulated in human cancers
and in several cancer cell lines. Indeed, we reported that
DUSP3 is highly expressed in cervical carcinomas and in
several cervix cancer cell lines [13]. This phosphatase is
also highly expressed in human prostate cancer and in
the LNCaP human prostate adenocarcinoma cell line
[14]. On the other hand, recent reports showed that
DUSP3 is downregulated in NSCLC and when overex-
pressed in these cells, it leads to decreased cell prolif-
eration and reduced tumor growth in a xenograft mouse
model [10]. In line with these findings, Min Gyu Lee’s
group reported recently that DUSP3 downregulation in
NSCLC tumors, when correlated with high levels of the
histone H3 lysine 36 (H3K36) demethylase, KDM2A, is
associated with poor prognosis for the patients [15]. In the
same study, the authors demonstrated that KDM2A acti-
vates ERK1/2 through epigenetic repression of DUSP3 ex-
pression via demethylation by H3K36 at the DUSP3 locus.
DUSP3 has also been found downregulated in breast car-
cinomas [16]. These studies clearly suggest that DUSP3
plays complex and contradictory roles in tumorigenesis
that could be cell type-dependent. However, most of these
studies were performed either in vitro, using recombinant
proteins, or in cell lines, using transient overexpression
or siRNA knockdown. Furthermore, all these studies were
focused on tumor cells without taking into account the
host cells. Therefore, the physiological function of DUSP3
is unknown.
We report herein that DUSP3 is highly expressed in
endothelial cells (EC), depletion of which causes an in-
hibition of EC in vitro tubulogenesis. To investigate the
physiological functions of DUSP3, we generated a new mu-
tant mouse strain deficient for Dusp3 gene. The obtainedDUSP3-deficient mice were viable and had no apparent
phenotype or spontaneous pathology, suggesting that
these mice could be useful to study DUSP3’s role in differ-
ent pathological conditions. Indeed, by applying different
in vivo, ex vivo and in vitro models, we provide evidence
that DUSP3 plays an important and non-redundant role
in angiogenesis.
Results
DUSP3 is highly expressed in human endothelial cells and
its expression is required for in vitro tubulogenesis
During our previous study investigating the role of
DUSP3 in human cervical cancer [13], we noticed that
all the blood vessel walls present in the tissue sections
were highly immunoreactive to anti-DUSP3 antibody,
suggesting that DUSP3 is highly expressed in endothelial
and/or smooth muscle cells, the 2 major blood vessels
cell components. To verify this hypothesis, we stained
paraffin embedded 4 μm serial sections of human cervix
biopsies with anti-DUSP3 or anti-Von Willebrand Factor
(vWF) antibodies. As shown in Figure 1A, endothelial
cells, identified based on the vWF staining in section 1,
were also positively stained with anti-DUSP3 antibody
in section 2, confirming DUSP3 high expression in EC.
To assess the role of DUSP3 in EC, we downregu-
lated its expression in the primary Human Umbilical
Vein Endothelial cells (HUVEC) using DUSP3 target-
ing siRNA and conducted a tube formation assay on
Matrigel. Cells were transfected with non-targeting siRNA
(siCTL) or with DUSP3 targeting siRNAs (siDUSP3-1 and
siDUSP3-2). The efficacy of the two different DUSP3
targeting siRNA was demonstrated by the significant
decrease of DUSP3 protein levels (Figure 1B). 72 hours
after transfection, equal cell numbers were seeded in a
24-well plate on a layer of pre-solidified Matrigel. After
24 h, the tube networks were visualized under phase
contrast microscope and photographed (Figure 1Ci).
Tube network were quantified by measuring total tube
length and number of tubes intersections. DUSP3 down-
regulation induced a significant decrease in tubulogen-
esis (Figure 1C) as quantified by a significant reduction
of network lengths and number of tube intersections
(Figure 1Cii) in both DUSP3 targeting siRNA condi-
tions compared to the siCTL condition.
Downregulation of DUSP3 inhibits in vitro angiogenic
sprouting
We previously found that DUSP3 depletion halted HeLa
cell proliferation [11]. We also reported that DUSP3 in-
hibition using small inhibitors blocked HeLa and Caski
cell proliferation [17]. Therefore, we postulated that the
decreased tubulogenesis in DUSP3 depleted EC could be
due to a defect in cellular proliferation. To investigate
this hypothesis, we measured HUVEC cells proliferation
Figure 1 DUSP3 is highly expressed in endothelial cells and its dowregulation inhibits in vitro tubulogenesis. (A) Immunohistochemistry
of DUSP3 and Von Willbrand Factor (vWF) on paraffin embedded 4 μm serial sections of human cervix biopsies. Section 1 was stained with
anti-vWF antibody and section 2 with anti-DUSP3 antibody. Sections 3 and 4 were stained with the secondary antibodies used to reveal vWF and
DUSP3 staining respectively. (B) HUVEC cells were transfected with non-targeting siRNA (siCTL) or with DUSP3 targeting siRNA (siDUSP3-1 and
siDUSP3-2). Efficiency of DUSP3 downregulation was measured at protein level using western blot 72 h after cell transfection. (Bi) Equal amount
of proteins were resolved by SDS-PAGE, and western blot was performed using anti-DUSP3 antibody or anti-GAPDH as loading control. (Bii)
Quantification and statistical analysis of DUSP3 protein expression in siCTL, siDUSP3-1 and siDUSP3-2 transfection conditions represented as a ratio
of DUSP3 on GAPDH. (Ci) Phase contrast microscopy of siCTL, siDUSP3-1 and siDUSP3-2 transfected HUVECs seeded on pre-solidified Matrigel
for 16 hours. (Cii) Quantitative analysis of the experiment shown in (Ci) obtained by measuring the tube lengths (left panel) and number of
intersections (right panel) from 10 fields. *, P < 0,05 and **, P < 0.01.
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HUVECs proliferation, as measured by thymidine in-
corporation (cpm), was not affected by DUSP3-depletion
in any of the conditions analyzed, namely in the EGM
rich medium, in the EBM minimum medium and in theEBM b-FGF growth factor (100 ng/mL)-supplemented
medium (Figure 2Ai). Efficiency of DUSP3 depletion is
shown in Figure 2Aii. We then hypothesized that the ob-
served decrease of tube formation in DUSP3-depleted con-
ditions could be due to a defect in endothelial sprouting.
Figure 2 DUSP3 downregulation affects HUVEC cell angiogenic sprouting but does not affect proliferation. (A) 72 hours after transfection
with siCTL, siDUSP3-1 or siDUSP3-2, HUVECs were trypsinized and 7.5 × 103 from each transfection condition were plated (in triplicate) and
cultured for an additional 24 hours. 3H-Thymidine was added for the last 4 h before cell harvesting. Radioactivity was counted using a scintillation
analyzer. (Ai) Statistical analysis from three independent experiments. Data are reported as mean ± SEM. (Aii) Western blot analysis using
anti-DUSP3 antibody and anti-GAPDH of one representative experiment showing DUSP3 depletion after siDUSP3-1 and siDUSP3-2 transfection.
Quantification of DUSP3 protein expression in siCTL, siDUSP3-1 and siDUSP3-2 transfection conditions are shown as a ratio of densitometry
values of DUSP3 on GAPDH bands. (Bi) Snapshots from phase contrast time-lapse movies of tube formation assay of HUVECs transfected with
siCTL or with siDUSP3 and seeded on Matrigel solidified matrix (Additional files 1 and 2). (Bii) Quantitative analysis of the snapshots shown in
(Bi) obtained by measuring the tube lengths (left panel) and number of intersections (right panel) from 10 fields. (Biii) Western blot and
quantification of DUSP3 protein expression in siCTL and siDUSP3-1 transfection conditions represented as a ratio of DUSP3 on GAPDH.
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copy. 72 hours after HUVECs transfection, equal numbers
of cells were seeded on pre-solidified-Matrigel in chamber
slides. Chambers were immediately transferred on the
x-y-z stage of Nikon microscope equipped with a cell
culture chamber at 37°C and 5% CO2. Images were ac-
quired every 10 min for 12 h. As demonstrated on the
Additional files 1 and 2, HUVECs transfected with siDUSP3
failed to form stable sprouts while upon siCTL transfection,
cells formed homogenous and vigorous sprouts (Additional
files 1 and 2 and Figure 2B). The quantification of sprout-
ing showed a significant decrease of tube length and num-
ber of intersections in the siDUSP3 condition compared
to siCTL condition at all time points analyzed during
the acquisition time period (Figure 2Bii). A representative
western blot showing the efficiency of DUSP3 depletion
for these experiments is shown in Figure 2Biii. These find-
ings were further confirmed using the spheroid-sprouting
assay. Indeed, DUSP3 silencing, as evidenced by DUSP3
downregulation (Figure 3Ai), blocked significantly the
angiogenic sprouting of HUVECs upon stimulation with
b-FGF as demonstrated by the decline of sprouts num-
bers per spheroid. However, when cells were stimulated
with PMA, as a positive control, sprouting of HUVECs
was equally induced in siCTL and siDUSP3 conditions
(Figure 3Aii-Aiii). These data suggest that DUSP3 contrib-
utes to growth factors-induced angiogenic sprouting.
DUSP3 depletion did not affect the MAPKs and EGFR but
affected PKC phosphorylation in HUVECs
In vitro DUSP3 most studied substrates are the mitogen-
activated protein kinases (MAPKs) ERK1/2 and JNK, but
not p38 [7-9,18]. In a previous study, we reported that
DUSP3 downregulation in HeLa cells halts cell prolifera-
tion and associates with the ERK1/2 and JNK1/2 hyper-
phosphorylation [11]. Therefore, we investigated if in
EC, DUSP3 depletion could lead to a modification of the
kinetic and/or the magnitude of ERK1/2 and or JNK1/2
activation. 48 h after HUVECs transfection using DUSP3
targeting siRNAs or siCTL, cells were washed and incu-
bated for 24 h in 2% serum containing-medium. Cells
were next washed and activated with 10 ng/ml of b-FGF
for 20 and 60 min at 37°C. Cells were then lysed and
western blots were performed using phosphospecific
antibodies against ERK1/2 activated forms. On the con-
trary to our previous findings in HeLa cells, we found
that DUSP3 depletion in HUVEC cells did not affect
ERK1/2 activation kinetic and magnitude (Figure 4Ai
and Aii). To assess the JNK activity in the absence of
DUSP3, we performed a SAPK/JNK kinase assay by
immunoprecipitating endogenous phospho-SAPK/JNK
from resting or b-FGF activated siCTL and siDUSP3
transfected cells. The activity of JNK was revealed by
incubating phospho-SAPK/JNK immunoprecipitates withrecombinant c-Jun, the JNK downstream target. SAPK/
JNK-induced recombinant c-Jun phosphorylation was
measured by a quantitative immunoblotting using
phospho-c-Jun (Ser63) and c-Jun antibodies. As demon-
strated by the results shown in Figure 4B, DUSP3 down-
regulation did not impact the kinetic and/or magnitude of
c-Jun phosphorylation suggesting that JNK activity is not
affected by DUSP3 depletion in EC.
A previous study has also reported that DUSP3 has a
minimal effect on MAPK phosphorylation but rather
target directly EGFR in non-small cell lung cancer cell
line [10]. To investigate if this is also the case in endo-
thelial cells, siCTL and siDUSP3 transfected HUVECs
were activated using EGF (100 ng/ml). EGFR was then
immunoprecipitated and immunoreacted with 4G10 anti-
phosphotyrosine antibody. As shown in Figure 4C, DUSP3
depletion did not affect EGFR tyrosine phosphorylation.
All together, these results suggest that DUSP3 does not
target MAPKs and EGFR in EC.
The fact that DUSP3 dowregulation in HUVECs does
not affect cell proliferation and ERK1/2 activation suggests
that DUSP3 is dispensable for the b-FGF-induced cell pro-
liferation. Since FGF signaling is also involved in prosurvi-
val via the activation of PI3k/Akt pathway, we investigated
if DUSP3 deficiency could lead to cell death or could im-
pact Akt activation. We found that DUSP3 depletion
in HUVECs was not associated with increased cell
death as measured by AnnexinV-PI (data not shown).
Consistent with this finding, DUSP3 downregulation did
not affect b-FGF-induced Akt phosphorylation (Fig-
ure 4D). FGF plays also a crucial role in cell migration and
angiogenesis. This effect is mediated through the PI3K
and PLCγ/PKC activation pathways [19]. Therefore, we
hypothesized that DUSP3 affects the PLCγ/PKC activation
pathway in our model. To investigate this hypothesis, we
subjected the resting and b-FGF activated HUVECs lysates
to immunoblot using phospho-PKC (Ser660) and found
that PKC was significantly hyper-phosphorylated at basal
levels in the absence of DUSP3 compared to the siCTL
condition. The activation with b-FGF increased fur-
ther the phosphorylation of PKC in all conditions.
However, in the DUSP3 downregulated conditions, the
phosphorylation of PKC plateaued earlier (at 20 min after
stimulation) than in siCTL (Figure 4E). These results sug-
gest that DUSP3-depletion-associated sprouting defect in
HUVECs could be the consequence of a defect in the PKC
activation pathway.
DUSP3-deficient mice are healthy and do not exhibit any
spontaneous phenotype
To gain insights into the function of DUSP3 in EC under
physiological conditions, we generated Dusp3-deficient
mice by targeted homologous recombination. The Dusp3
gene was disrupted in 129/SvJ murine embryonic stem
Amand et al. Molecular Cancer 2014, 13:108 Page 6 of 18
http://www.molecular-cancer.com/content/13/1/108(ES) cells by the replacement of exon II with a neo gene ex-
pression cassette (Figure 5A). Four ES clones, containing
the targeted disrupted allele, were obtained and injected
into blastocysts of C57BL/6 J mice. Germline transmission
was obtained from 2 independent ES cell clones. Southern
blot analysis confirmed the presence of the disrupted exon
(Figure 5B). Heterozygous mice did not show morpho-
logical abnormalities and were bred to obtain mice homo-
zygous for the disrupted allele. Dusp3−/− mice showed no
detectable protein immunoreactivity with anti-DUSP3
antibody in protein extracts from mouse embryonic fibro-
blasts (MEFs) compared to wild-type mice (Figure 5C).
These mice were viable, fertile, developed normally and
had no apparent or spontaneous pathology. These finding
suggest that DUSP3 is dispensable for embryogenesis,
adult mice development and homeostasis. A second alter-
native could be that another DUSP is compensating for
DUSP3 deficiency.
DUSP3 deficiency affects in vivo and ex vivo angiogenesis
The altered expression of DUSP3 in several human can-












































Figure 3 DUSP3 downregulation affects HUVEC spheroids sprouting.
siCTL, siDUSP3-1 and siDUSP3-2 transfection conditions represented as a ra
sprouting assay performed with endothelial cells as indicated with siCTL, si
(10 ng/mL). (Aiii) The mean cumulative number of sprouts per spheroid w
*, P < 0,5; **, P < 0,01.in EC tubulogenesis prompted us to investigate if in vivo
DUSP3 deficiency could also lead to a decrease in neovas-
cularization and angiogenesis. We have used three well
established models of angiogenesis, previously validated to
assess the function of different metalloproteinases in
angiogenesis [20-22]. To perform our comparative studies
and assess the angiogenic response to b-FGF in DUSP3+/+
and DUSP3−/− mice, 500 μL of Matrigel containing
human b-FGF (250 ng/mL) and Heparin (0.0138 mg/mL)
were injected subcutaneously to the two flanks of
DUSP3+/+ and DUSP3−/− mice (n = 15 mice in each group).
Quantification of plugs vascularization was performed
10 days after injection. As shown in Figure 6A, plugs re-
trieved from DUSP3−/− mice were clearly less vascularized
compared to the ones harvested from DUSP3+/+ mice.
This was confirmed after homogenization of the Matrigel
plugs and measurement of their hemoglobin (Hb) content
(Figure 6B). Indeed, Matrigel from the DUSP3−/− mice
showed more then 40% decrease of Hb compared to the
plugs from DUSP3+/+ mice. To further confirm these find-
ings, in a separated experiment, mice were injected with















(Ai) Western blot and quantification of DUSP3 protein expression in
tio of DUSP3 on GAPDH. (Aii) Representative images of spheroid
DUSP3-1 and siDUSP3-2 in the presence of PMA (75 ng/mL) or b-FGF
as assessed after 48 hours. Results are presented as mean ± SEM.































































































































Figure 4 (See legend on next page.)
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Figure 4 DUSP3 depletion affects PKC activation but is dispensable for ERK1/2, JNK and EGFR in HUVEC cells. HUVECs were transfected
with non-targeting siRNA (siCTL) or with DUSP3 targeting siRNA (siDUSP3-1 and siDUSP3-2). 24 h before stimulation, cells were washed and let to
rest overnight in 2% serum containing medium. Cells were then activated with b-FGF (10 ng/mL) for the indicated time points theb lysed. Cell
lysates were resolved on SDS-PAGE and immuno-reacted with (Ai) anti-phospho-ERK1/2 (Thr202/Tyr204) and ERK as an internal loading control,
(Aii) anti-DUSP3 and anti-GAPDH (Aiii) Quantification of the phosphorylation levels or ERK was determined by densitometric analysis and is
shown as a ratio of pERK/ERK. Results are presented as mean ± SEM and are representative of 3 independent experiments. (B) SAPK/JNK kinase
assay. JNK was immunoprecipitated from siCTL and siDUSP3 transfected cell lysates. After transfer of the JNK immunoprecipitates, nitrocellulose
membranes were immuno-reacted with anti-phospho-c-Jun and anti-c-Jun antibodies (Bi). Quantification of the phosphorylation levels or JNK
substrate, c-Jun, was determined by densitometric analysis and is shown as a ratio of p-c-Jun/c-Jun (Bii). (C) EGFR phosphorylation. EGFR was
immunoprecipitated from non-stimulated and EGF (100 ng/ml) stimulated HUVECs transfected with siCTL or with siDUSP3. Immunoprecipitates
were immunoreacted with anti-phosphotyrosine antibody 4G10. Membranes were stripped and re-bloted with anti-EGFR antibody. (D) Western
blot for p-Akt and Akt on cell lysate from FGF stimulated siCTL and siDUSP3 transfected conditions. (Ei) Western blot for phospho-PKC (Ser660)
on cell lysates from FGF stimulated cells in the conditions indicated. ERK was used as a loading control. (Eii) Quantification of the phosphorylation
levels or PKC was determined by densitometric analysis and is shown as a ratio of phospho-PKC/ERK. Results are presented as mean ± SEM and
are representative of 4 independent experiments. *p < 0,05; **p < 0.01; ***p < 0,001.
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was next visualized under epifluorescence microscope and
fluorescence was quantified using Imaris software. Matri-
gels retrieved from DUSP3−/− mice showed a minimal
vascularization as demonstrated by the level of FITC-
dextran fluorescence intensity (Figure 6C-D) and by the
CD31+ staining (Figure 6C and E).
The decrease of Matrigel vascularization in DUSP3−/−
mice was further confirmed by the significant decrease
of representative endothelial cells transcripts, such as
Pcam1 (CD31) and Cdh5 (VE-Cad/Cd144), and pericytes
transcripts, such as Acta2 (aSMA) and Pdgfrb (CD140b)
in the Matrigel plugs retrieved from DUSP3−/− com-
pared to the ones from DUSP3+/+ mice (Table 1).
We next investigated the angiogenic role of DUSP3 in
the context of tumor development by using a rapid
tumor-induced model. Mice were subcutaneously injected
with 106 of Lung Lewis Carcinomas cells (LLC) and tu-
mors were removed 7 days later. As shown if Figure 6F,
the Hb content of the homogenized tumor mass from the
DUSP3−/− mice was reduced by 30% compared to the ho-
mogenates from the DUSP3+/+ mice (Figure 6F-G). LLC
tumors weights were reduced slightly but not significantly
in the DUSP3−/− compared to DUSP3+/+ mice (Figure 6F
and H). These results demonstrate that the tumor-induced
angiogenic response is defective in mutant mice.
To further investigate the contribution of DUSP3 in neo-
vessel formation, aortic explants issued from DUSP3+/+
and DUSP3−/− mice were embedded in three dimensional
type I collagen gel in non-complemented medium, autolo-
gous serum complemented or in b-FGF complemented
medium (Figure 7A). The microvessel outgrowth were
quantified by determining the number of intersections in
function to the distance to the aortic ring as previously
reported [24]. As evidenced by Figure 7, sprout dens-
ity was significantly reduced (p < 0,001) in the aortas
derived from DUSP3−/− mice when stimulated with b-FGF
growth factor (Figure 7A-B). Furthermore, the measuredlength achieved by vessels was reduced in the absence of
DUSP3 upon stimulation with b-FGF. Indeed, maximal
vessel growth for DUSP3−/− aortas was: Lmax (mm) =
0.48 ± 0.23 and for DUSP3+/+ aortas: Lmax = 1.195 ± 0.11
(p Value = 0.021). Differences were not statistically sig-
nificant neither in the non-stimulated nor in the serum-
stimulated conditions (Figure 7A-B).
All together, these results suggest that, in vivo, DUSP3
plays a key role in neoangiogenesis.
Discussion
The physiological function and possible involvement of
the A-DUSP family members in cancer is largely un-
known. The lack of knockout mice for A-DUSPs is prob-
ably one of the major limitations in the determination of
the physiological function of these phosphatases. So far,
out of 19 A-DUSPs, only 3 were disrupted in mice,
STYX [25], DUSP14 [26] and laforin [27]. However, the
role of these phosphatases in cancer and angiogenesis
were not investigated in these mutant mice. Thus, the
physiological function of A-DUSPs in cancer and angio-
genesis is still unknown.
We report here the generation of a new mouse strain
lacking Dusp3 gene, encoding for the atypical dual speci-
ficity phosphatase DUSP3. The mutant DUSP3−/− mice
develop normally and do not have any spontaneous evi-
dent pathology, making them a good in vivo tool to in-
vestigate the role of DUSP3 in different diseases. By
applying different in vivo and ex vivo models to these
knockout mice, we provide evidence for a new physio-
logical role of DUSP3 in neovascularization. We also re-
port that DUSP3 is highly expressed in human endothelial
cells and demonstrate its essential role for in vitro primary
human endothelial cell angiogenic sprouting function.
The fact that DUSP3-deficient mice are born displaying
no vascular defects under normal conditions could be ex-
plained by a redundant function of DUSP3 shared with
other DUSPs. Indeed, several DUSPs have overlapping




































































Figure 5 Dusp3 deficient mice generation by targeted homologous recombination. (A) Schematic diagram showing part of the Dusp3
gene locus, the targeted Dusp3 construct and the resulting targeted allele. Recombination events are indicated by open white boxes and show
the replacement of a 8.2 kb Dusp3 genomic fragment containing exon II by the pPNT-Neo cassette. (B) Southern blot analysis of ES cells genomic
DNA following digestion with XbaI using a 5’ external Probe P as indicated in (A). The autoradiography revealed the 8.2 kb (wild-type) and 4.5 kb
(targeted) fragments. The stars represent the ES cell lines used for microinjection of mouse blastocysts. (C) Western blot analysis of DUSP3 protein
expression in MEF cell extracts from 6 Dusp3+/+ and 6 Dusp3−/− mice. GAPDH was used as an internal control.
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it difficult to assign a specific physiological role for a spe-
cific DUSP in a specific tissue. It is conceivable that condi-
tional knockout mice lacking DUSP3 only in the
endothelial cells may display a vascular phenotype during
embryonic vascular development than the full knockout
mice. However, we found that DUSP3-deficiency prevented
neo-vascularisation of Matrigel plugs and LLC xenograft
tumors suggesting that DUSP3 plays an important and
non-redundant function in tumor-induced angiogenesis.
Using microarray analysis, we evaluated the expression
levels of all DUSPs transcripts in the Matrigel plugs ex-
tracts retrieved form DUSP3−/− and WT mice. We found
that among all DUSPs (typical and atypical), DUSP1/
MKP1 and DUSP23/VHZ were significantly downregu-
lated in Matrigel plugs retrieved RNAs (Table 2) and we
did not observe an increase in any DUSP in the absence
of DUSP3. Altered expression of DUSP1/MKP1 has been
reported in different human cancer (reviewed in [28]).In angiogenesis, DUSP1/MKP1 expression is associ-
ated with increased invasiveness of NSCLC due to an in-
creased expression of VEGFC, suggesting that DUSP1
inhibition could be a good strategy to inhibit tumor inva-
sion and angiogenesis [29]. Therefore, the observed de-
crease of neo-angiogenesis in our model could also be due
to the decreased DUSP1/MKP1 expression. The other
possibility could be that the observed decrease of DUSP1
reflects the decreased number of endothelial and smooth
muscle cells in the Matrigels infiltrates (Table 1). As for
DUSP23/VHZ, little is known about this phosphatase
function. However, DUSP23/VHZ is highly expressed in
several human cancers and could play a role in cell cycle
regulation [30]. The cellular distribution of DUSP23 is not
known. Therefore, it is difficult to conclude if, in our case,
the observed decrease of this phosphatase transcript in
DUSP3−/− retrieved Matrigels is due to DUSP3 deficiency
or reflects the decrease of EC and smooth muscle cells in-
filtration in Matrigels.
Figure 6 (See legend on next page.)
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Figure 6 DUSP3 deficiency affects in vivo angiogenesis. (A-E) DUSP3+/+ and DUSP3−/− mice were injected subcutaneously in the flanks with
0.5 mL of Matrigel together with human b-FGF (250 ng/mL) and Heparin (0,0138 μg/mL). Ten days after injection, mice were sacrificed and
Matrigels were removed. Representative photographs are shown in (A) from eight mice from each group. (B) Quantification of angiogenesis
within the Matrigel plugs was achieved by measuring hemoglobin (Hb) concentration in the Matrigel homogenates and was reported as mg of
measured Hb per mg of Matrigel. Results are presented as means ± SEM, n =15 in each group. (C) FITC-dextran was i.v. injected to DUSP3+/+ and
DUSP3−/− mice 5 min before removal of subcutaneously implanted Matrigel plugs. Frozen sections were stained using Alexa 594 conjugated
anti-CD31 and DAPI and visualized using fluorescent microscope. Representative micrographs of FITC-Dextran (green), CD31 (red), DAPI (blue)
stainings and a merge of all are shown. (D-E) Quantification of CD31+ cells in blood vessel sections per mm2 of Matrigel section (D) and FITC
dextran intensity (arbitrary units) in Matrigel sections (E) from DUSP3+/+ and DUSP3−/− mice. Results are presented as means ± SEM, n = 10 in each
group. Data are presented as mean ± SEM from 3 independent experiments (n = 15). (F-H) 106 LLC cells were subcutaneously injected in the flank
of DUSP3+/+ and DUSP3−/− female mice. 7 days later, tumors were removed and homogenized for Hb measurement. Representative photographs
of the tumors are shown in (F) from six WT and seven DUSP3-KO mice. (G) Hb measurement in the tumors homogenates shown in F. (H)
Weights of the tumors retrieved from the mice. Data are presented as mean ± SEM. *p < 0.05 (t-student test).
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prevented the sprouting in response to the angiogenic
growth factor b-FGF. This finding was further supported
by the significant decrease of angiogenic sprouting in the
HUVECs spheroid model after in vitro downregulation of
DUSP3 using RNA interference. Although the underlying
mechanism is not clear, these findings suggest that DUSP3
plays an important role in the b-FGF receptor signaling
pathways. FGF signalings are involved in a plethora of
biological processes leading to: activation of cell prolifera-
tion, inhibition of apoptotic signals, activation of cell migra-
tion in different cell types and promotion of angiogenesis.Table 1 Representative gene expression profile of different cel
versus WT



















Data presented are extracted from a genome-wide microarray dataset obtained using
the ratio of the average values obtained from 2 pools of 3 Dusp3-knockout each on 2
using unpaired student’s t test).FGF activates cell proliferation mainly through the
Raf-MEK-ERK MAPK pathway (reviewed in [19]). The
fact that DUSP3 dowregulation in HUVECs did not
affect cell proliferation and ERK1/2 activation suggests
that DUSP3 is dispensable for the b-FGF-induced cell pro-
liferation. We can also exclude the involvement of DUSP3
in FGF PI3K/Akt pro-survival/anti-apoptotic pathway as
DUSP3 depletion did not impact HUVECs apoptosis. On
the other hand, the phosphorylation of Akt was normally
induced in DUSP3-depleted HUVECs. FGF plays also a
crucial role in cell migration and angiogenesis. This effect
is mediated through the PI3K and PLCγ/PKC activationl populations [23] in Matrigel plugs from Dusp3-knockout
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Figure 7 (See legend on next page.)
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Figure 7 Ex-vivo microvasculature outgrowth from DUSP3+/+ and DUSP3−/− mice aortic rings. (A) Phase contrast micrographs of thoracic
aortas from 17 weeks old DUSP3+/+ and DUSP3−/− mice grown for 9 days in collagen additive-free (no stimulation), in 2.5% serum containing
collagen gels or in 20 ng/mL of b-FGF-supplemented collagen gels. Magnification ×25. (B) Computerized quantification of number of microvessel
intersections and maximal length of vessels from culture conditions shown in A. X axis represents the length of the aortic microvessel outgrowth
and Y-axis represents the number of intersections of the microvessels. The arrows in the b-FGF stimulated conditions indicates the maximal vessel
growth, Lmax (mm) for DUSP3−/− and for DUSP3+/+ aortas. ***p <0.001 (t-student test).
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depletion in HUVECs affected PKC basal and b-FGF in-
duced phosphorylation. PKCs represent a large family of
enzyme activated by two secondary messengers, calcium
(Ca2+) and diacylglycerol (DAG). Ca2+ increases the af-
finity of PKC for lipids and DAG induces a high affinity
interaction with the membrane leading to its activation
[31,32]. To be ready for activation by Ca2+ and DAG,
PKC is first phosphorylated by both phosphoinositide-
dependent kinase 1 [33] and by autophosphorylation [34].
The autophosphorylation of PKC on serine 660 residue
is important for the stability of the enzyme conform-
ation and downstream signal transduction [35,36]. In ab-
sence of DUSP3, we found that this autophosphorylation
site (Ser660) is hyperphosphorylated, suggesting that PKC
is in a ready state to be activated. However, the anti-
phospho-PKC Ser660 antibody used detects endogenous
levels of several PKC isoforms. To investigate which PKC
isoform is affected by DUSP3 depletion, immunoprecipita-
tion of all the isoforms, followed by immunoblotting with
phospho-PKC bII Ser660 is required. What is clear so far
is that DUSP3 is involved in FGF-induced PKC activation
in MAPKs-independent manner. Upon activation with
FGF, DUSP3-depleted cells showed a very slight increase
in the phosphorylation of the autophosphorylation site of
the PKC family proteins compared to the control. This
could be due to the fact the hyperactivated status of PKC
at basal levels leads to an unresponsive signaling pathway.
We have also investigated if the most recently identi-
fied DUSP3 substrate, EGFR in H1299 cells [10], could
be affected by DUSP3 depletion in HUVECs. EGFR is an
important player in diverse biological processes and is
actually targeted by different approaches in various human
malignancies [37]. Tyrosine phosphorylation is an import-
ant post-translational modification for EGFR-induced sig-
naling after ligand binding. We found that EGFR tyrosine
phosphorylation was not affected by DUSP3 deficiency in
HUVEC cells neither at basal levels, nor after EGF activa-
tion suggesting that DUSP3 is not targeting EGFR in endo-
thelial cells. These results were compatible with recent
study where Wagner et al. showed that EGFR was not reg-
ulated by DUSP3 in the primary NSCLC tumor cells and
in the NSCLC cell line H460 [15].
In the DUSP3−/− mice, we also found that the activity
of ERK1/2 and JNK1/2 were not affected by DUSP3 defi-
ciency in B cells, T cells, macrophages and platelets(unpublished observations). However, we failed in testing
this in mice primary endothelial cells as the purification
of sufficient number of these cells without affecting the
basal activity of MAPKs was challenging. This is not the
first time that previously characterized DUSP substrate
specificity is not confirmed in a knockout mice model.
Indeed, deficiency of DUSP2/PAC1, a known phosphat-
ase for ERK and p38, does not lead to enhanced ERK
and p38 phosphorylation but rather causes an enhanced
JNK phosphorylation, suggesting a crosstalk between the
different MAPKs that contribute to the observed changes
in DUSP2−/− mice [38]. Similarly, knockout of DUSP10/
MKP5, a phosphatase known to target p38, does not
cause p38 hyperphosphorylation [39]. These inconsisten-
cies are probably due to the use of in vitro overexpression/
downregulation systems during previous characteriza-
tions of DUPS’s substrate specificity, which may not
faithfully reflect the outcomes from DUSP-deficient pri-
mary cells. Alternatively, the lack of a particular DUSP
may be compensated by other DUSPs.
Conclusions
Taken together, the present study provides evidence for
an unexpected physiological role of the dual specificity
phosphatase DUSP3 as new key mediator of neovasculari-
zation by affecting at least the b-FGF-induced endothelial
cell sprouting most probably via the PKC pathway. How-
ever, further investigations are required to shed light into
the role of DUSP3 in angiogenesis and the molecular
mechanism in the b-FGF-induced, and perhaps other
receptor signaling pathways, involved in angiogenic
sprouting.
Methods
Generation of DUSP3 knockout mice by disruption of
Dusp3 locus
The DUSP3 knockout (KO) mouse was generated by re-
placing the Exon II with the Neo gene by homologous
recombination. A 2.3 Kb fragment containing Exon I
and a 4.5 Kb fragment containing the 5’ region of Intron
II of the Dusp3 gene were cloned inside the plasmid
pPNT and the plasmid was transfected into the 129/SvJ
embryonic stem (ES) cell line by electroporation. G418
and Ganciclovir resistant ES clones were screened by
PCR using a forward primer located in the Dusp3 gene,
outside the 2.3 kb fragment cloned in the plasmid, and a
Table 2 Dusps genes expression profile from
Dusp3-knockout versus WT Matrigel plugs
Gene name Protein names Ratio Dusp3-KO/WT P value
Typical Dusps
Dusp1 MKP1 0.60 0.041*
Dusp2 PAC-1 1.0 0.96
Dusp4 MKP2 0.48 0.18
Dusp5 DUSP5; hVH3; B23 NP
Dusp6 MKP3 1 0.9
Dusp7 MKPX 0.9 0.6
Dusp8 DUSP8 0.97 0.88
Dusp9 MKP4 ND
Dusp10 MKP5 1.5 0.23





Dusp11 PIR1 1 0.75
Dusp13 MDSP; TMDP; DUSP13 1.8 0.38
Dusp14 MKP6 0.84 0.51
Dusp15 VHY 1.1 0.56
Dusp18 LMW-DSP20 0.54 0.11
Dusp319 SKRP1; LMW-DSP3 1.3 0.057
Dusp21 LMW-DSP21 ND
Dusp22 JSP-1; JKAP; MKPX; VHX 1.4 0.078
Dusp23 LDP-3; VHZ 0.85 0.04*
Dusp26 MKP8, NEAP 1.3 0.71
Dupd1 DUPD1 2.5 0.18
Dusp28 VHP 1.1 0.31
Styx STYX 1.1 0.43
Data presented in this table are extracted from a genome-wide microarray
dataset obtained using Illumina’s multi sample format Mouse WG-6 V2
BeadChip. Data are presented as the ratio of the average values obtained from
2 pools of 3 Dusp3-knockout each on 2 pools of 3 WT mice each and the
corresponding p-value. (*p < 0.05 determined using unpaired student’s t test).
ND: not detected. NP: no probe/not present on the microarray chip.
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homologous recombination was verified by Southern
hybridization analysis, detecting an additional 4.5 Kb frag-
ment after XbaI digestion and hybridization with a probe
located in the 5’ region of the Dusp3 gene. Two recombin-
ant ES cell lines were injected into blastocysts of C57BL/
6 mice producing chimeras that were mated with
C57BL/6 mice to generate heterozygous founders. ES
transfection and blastocyst injection were performed at
the Moores Cancer Center/Transgenic and Gene Tar-
geting core facility at UCSD. http://cancer.ucsd.edu/Re-
search/Shared/tgm/default2.asp. Heterozygous mice weremated to generate +/+ and −/− littermates to be used for
experimentation. Mice were weaned and ear-marked at
day 21. At week 4, 2 mm of tail was cut for genotyping
using a surgical blade. Total DNA was extracted from tail
tip using High Pure PCR template preparation kit (Roche,
Vilvoorde, Belgium) and 0.1 μg was used as a template in
50 μl of a final reaction mixture which contained the
Dusp3 primers 5′GTGTGAGCTGCACTTTCCAA3′ and
5′GGTGACTGGGTGAAGAATGG3′, together with the
Neo primer 5′TTGCCAAGTTCTAATTCCATCAGA3′.
The reaction generates a 456 bp fragment from the Dusp3
gene and a 365 bp fragment from the recombinant
construct.Ethical statement
All mice experiments and procedures were carried out
following the guidelines and in agreement with the ani-
mal ethics committee of the University of Liège. All the
work was covered by the ethical licence: 858 “under-
standing the role of DUSP3 in angiogenesis”.Antibodies and reagents
Anti-Von Willebrand Factor (vWF) antibody was from
Dako (Dako, Heverlee, Belgium). Anti-DUSP3 antibody
used for immunohistochemistry, basic-Fibroblast growth
factor (b-FGF) and heparin were from R&D (R&D Systems,
Minneapolis, MN). Anti-DUSP3 antibody used for western
blots, as well as the anti-CD31, Matrigel and Dispase
were from BD Biosciences (BD Biosciences, San Jose, CA).
Anti-phosphotyrosine antibody (4G10) was from Millipore
(Millipore, Overijse, Belgium). Anti-phospho-ERK1/2
(Thr202/Tyr204), anti-ERK1/2, anti-cJun, anti-pospho-
Akt (Ser473), anti-Akt, anti-EGFR, anti-phospho-PKC
pan (Ser660) antibodies and SAPK/JNK kinase assay
kit were all from Cell Signaling (Cell Signaling, Danvers,
MA). HRP conjugated anti-mouse and anti-rabbit sec-
ondary antibodies and enhanced chemiluminescence kit
(ECL) were from GE Healthcare (GE Healthcare Europe
GmbH, Diegem, Belgium). Double stranded siRNA used
as a non-targeting control (siCTL) was from Dharmacon
(Thermo Scientific-Dharmacon, Erembodegem-Aalst,
Belgium). Double stranded siRNAs used for DUSP3 silen-
cing were from Eurogentec (Eurogentec, Seraing, Belgium)
and sequences were siDUSP3-1 (GGCAGAAGAUGGAC
GUCAA), siDUSP3-2 (GGUCCUUCAUGCACGUCAA).
Anti-rat Alexa 594 secondary antibody were from Life
Technology (Life Technology, Gent, Belgium). GeneTransII
was from Mo Bi Tec (Mo Bi Tec, Gottingen, Germany).
[3H] thymidine was from Perkin Elmer (Perkin Elmer,
Zaventem, Belgium). Anti-GAPDH antibody and Fluorescein
isothiocyanate-dextran (FITC-Dextran) were from Sigma
(Sigma-Aldrich, Diegem, Belgium). Collagen R was from
Serva (Serva, Heidelberg, Germany).
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proliferation
Human Umbilical Vein Endothelial Cells (HUVEC), EBM
medium and EGM Singlequot were purchased from Lonza
(Lonza, Basel, Switzerland). HUVECs were maintained in
EGM (EBM+ EGM Singlequot). Early cell passages (2 to
6) were transfected with non-targeting siCTL (150nM) or
with 2 different DUSP3 targeting siRNA (150nM) using
GeneTransII transfection reagent as a vehicle (3.5 μL/
1 mL). HUVEC were used for experiments 72 hours after
transfection. Cellular proliferation was measured as previ-
ously reported [11,17]. The Lewis Lung Carcinoma (LLC)
cells were cultured in DMEM (Lonza, Basel, Switzerland)
supplemented with 10% heat-inactivated fetal bovine
serum in a humidified atmosphere of 5% CO2 at 37°C.
Immunohistochemistry
Human cervix carcinoma paraffin embedded serial sec-
tions (4 μm) were incubated during one hour in the
oven at 60°C, deparaffinized and rehydrated using suc-
cessive baths as follow: 2 × 5 min in xylol, 2 × 2 min in
100% ethanol, 1 × 1 min in 95% ethanol, 1 × 2 min in
70% ethanol and 2 × 2 min in dH2O. Antigen retrieval
was performed using Target retrieval solution (Dako) for
40 min at 99°C. After 20 min at room temperature (RT),
endogenous peroxydases were inhibited using Peroxydase
blocking solution (Dako) during 10 min at RT. Back-
ground staining was reduced by incubating the slides
in 10% normal goat serum/PBS for 30 min at RT. Sec-
tions were then subsequently incubated with the primary
anti-DUSP3 (dilution: 1/50) or anti-vWF (dilution: 1/200)
antibodies for 1 h at RT then with the HRP conjugated
anti-mouse or anti-rabbit secondary antibody at 1/200
dilution during 1 h at RT. Staining was revealed using
3,3’-Diaminobenzidine (DAB) chromogen and slides were
counterstained with haematoxylin.
Tubulogenesis Matrigel assay
To perform tube formation assay, 200 μL of Matrigel
were put in 24 well culture plates and incubated for
2 hour at 37°C to allow gelling. Dissociated (3 × 103)
HUVECs were diluted in the appropriate medium and
added onto the Matrigel layer. After 24 h, tube forma-
tion was visualized using phase-contrast microscopy.
Total tube length and number of intersections were
quantified using Image J software (National Institutes of
Health, Bethesda, MD).
Time-lapse video microscopy
siCTL and siDUSP3 transfected HUVECs (105 cells)
were seeded on gellified Matrigel layer in 2 wells Lab-Tek
chamber slides (Thermo Fisher Scientific, Waltham, MA,
USA) and transferred to the stage of a Nikon A1R micro-
scope (Nikon, Wavre, Belgium) equipped with x, y and zaxes and maintained at 37°C and 12 hours. Images were
acquired every 10 minutes using Nis Elements software
(Nikon, Wavre, Belgium) and saved as ND2 files. Individ-
ual files were then combined and processed into AVI
Movies using Nis Elements software. Representative snap
shots were taken from siCTL and siDUSP3 conditions at
different time intervals.
In vivo Matrigel angiogenesis assay and LLC cells injection
DUSP3+/+ and DUSP3−/− mice were subcutaneously
injected in the two flanks with 500 μl of Matrigel supple-
mented with b-FGF (250 ng/ml) and Heparin (0.0138 mg/
ml). Ten days later, Matrigel plugs were carefully harvested,
weighted and digested with Dispase for 1 h at 37°C. The
hemoglobin content was determined by a colorimetric
assay using Drabkin’s reagent (Sigma-Aldrich). In separated
experiments, 5 min prior mice sacrifice, freshly prepared
FITC-Dextran (100 mg/kg) was injected in the tail vein.
Matrigel plugs were frozen in Tissue-tek for subsequent
immuno-fluorescence analysis.
For LLC tumor cells injection, mice were subcutane-
ously injected in the flanks with 106 LLC cells. Seven
days later, tumors were carefully harvested, weighted
and mechanically grounded using a homogenizer. The
hemoglobin content was determined using Drabkin’s re-
agent colorimetric assay.
Immunofluorescence staining
For immunofluorescent staining of frozen Matrigel plugs,
sections of 7 μm were fixed in ice-cold acetone for 2 min
then in methanol (4°C) for 5 min. After blocking in PBS
containing 10% normal goat serum for 30 min at RT,
slides were incubated for one hour with anti-CD31. Slides
were then washed. Immunoreactivity was revealed using
anti-rat Alexa 594 secondary antibody. CD31 staining
and injected FITC-dextran fluorescence were visualized
under Olympus Vanox AHBT3 epifluorescent microscope
(Olympus, Aartselaar, Belgium). The number of CD31+
blood vessels sections and total FITC-Dextran fluores-
cence intensity were quantified using Imaris software
(Imaris, Bitplane, Zurich, Switzerland).
Mouse aortic ring assay
Mouse aortic ring assay was performed as previously
described [40]. Briefly, 1 mm long mice aortic rings ex-
plants were cultured in collagen gel (1,5 mg/ml). The
aortic rings were either non-stimulated, stimulated with
autologous serum or stimulated with 20 ng/ml of b-FGF.
The explants were cultured for 9 Days at 37°C and 5%
C02 and photographed using Zeiss Axiovert 25 (Zeiss,
Zaventem, Belgium). Microvessel intersections number
and maximal length of vessels outgrowth were quanti-
fied with the Aphelion 3.2 software from Adsis (Meythet,
France).
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To generate the spheroids, we proceeded as previously
reported [41]. Briefly, HUVECs resuspended in EBM
containing 0.24% high viscosity methyl cellulose (Sigma-
Aldrich) were seeded in 96 well round bottom non-adherent
plates and cultured overnight at 37°C. Each spheroid
contained 103 cells. Single spheroids were collected, em-
bedded in rat tail collagen type 1 gel (Corning, Seneffe,
Belgium) and cultured for 48 hours at 37°C in 2% FBS
supplemented EBM with 75 ng/ml phorbol-12 myristate
13-acetate (PMA) or 10 ng/ml b-FGF. To quantify the
sprouting, the mean number of sprout in each condition
was counted.
Cell lysates, immunoprecipitation, western blot and SAPK/
JNK Kinase assay
For western blot experiments, cells were stimulated for
the indicated time points and lysed using RIPA buffer
(50 mMTris-HCl (pH = 8.0), 150 mM NaCl, 1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS, 1 mM orthovana-
date, complete protease inhibitor cocktail tablets EDTA
free and 1 mM phenylmethylsulfonyl fluoride) on ice
during 20 minutes. Lysates were next clarified by centri-
fugation at 21000 g during 20 min at 4°C. The resulting
supernatants were collected and protein concentrations
were determined using the colorimetric Bradford reagent
(Bio-Rad, Nazareth, Belgium). Samples were next dena-
turated at 95°C in Laemmli buffer. To investigate the
SAPK/JNK activity, we used the SAPK/JNK kinase assay
kit following the instructions of the manufacturer.
Briefly, cells were stimulated for the indicated time and
lysed with the cell lysis buffer provided. Cell lysates were
incubated overnight at 4°C with Phospho-SAPK/JNK
Rabbit mAb sepharose beads with constant agitation.
Kinase assay was performed by adding c-Jun recombin-
ant protein and ATP to the beads with 1× Kinase
buffer and incubated for 30 min at 30°C. The reaction
was stopped by adding SDS Laemmli buffer and
boiled at 95°C for 5 min. Samples were then run on SDS-
PAGE gel and transferred to Hybond-nitrocellulose mem-
branes. To block the non-specific binding sites, mem-
branes were incubated for one hour in Tris-buffered
saline-Tween 20 containing 5% of non fat milk or 3%
BSA. Membranes were next incubated with anti-Phospho-
c-Jun and anti-c-Jun. Immunoprecipitations of EGFR were
carried out following previously reported protocols [42].
To evaluate the efficiency of siRNA transfection, the phos-
phorylation of ERK1/2 and Akt, cell lysates from trans-
fected endothelial cells were resolved by SDS-PAGE
and transferred onto nitrocellulose membranes. The
membranes were next immunoblotted with anti-DUSP3,
anti-phospho-ERK1/2 and anti-phospho-Akt antibodies.
Membranes were next stripped, blocked and immuno-
blotted with anti-GAPDH, anti-Akt and anti-ERK1/2antibodies for normalization. Immunoreactivity was then
revealed using HRP conjugated secondary antibodies. The
blots were developed by enhanced chemiluminescence
(Amersham, Gent, Belgium) according to the manufac-
turer’s instructions.
Microarray analysis and gene expression profiles
Total RNA was isolated from b-FGF containing Matrigel
plugs retrieved from DUSP3+/+ and DUSP3−/−mice 10 days
after sub-cutaneous injection. RNA was prepared using
Trizol reagent (Roche). The yield of the extracted RNA
was determined using spectrophotometer by measuring
the optical density at 260 nm. The purity and quality of the
extracted RNA were evaluated using the Experion RNA
StdSens Analysis kit (Bio-Rad Laboratories, Hercules, CA).
High quality RNA with RNA Quality Indicator (RQI)
score greater than 8 was used for microarray experiment.
Gene expression profiling was performed using Illumina’s
multi-sample format Mouse WG-6 V2 BeadChip contain-
ing 45281 transcripts and profiles six samples simultan-
eously on a single chip (Illumina Inc., San Diego, CA).
For each sample, 250 ng of total RNA was labeled using
Illumina Total Prep RNA Amplification kit (Ambion,
Austin, TX) according to the manufacturer’s instructions.
Briefly, double stranded cDNA was synthesized using
T7-oligo (dT) primers and followed by an in vitro tran-
scription reaction to amplify antisense RNA (aRNA), while
biotin was incorporated into the synthesized aRNA probe.
The aRNA probe was then purified and quantified using a
NanoDrop spectrophotometer (Thermo Fisher Scientific,
Waltham, MA).
Biotinylated cRNA probe was hybridized to the Mouse
WG-6 V2 BeadChip Array (Illumina). Labeled aRNA
(1500 ng) was used for hybridization to each array. The
hybridization, washing and scanning, were performed ac-
cording to the manufacturer’s instructions. The arrays were
scanned using a BeadArray Reader (Illumina). The micro-
array images were registered and extracted automatically
during the scan according to the manufacturer’s default
settings. Raw microarray intensity data were analysed with
the Genome Studio software normalized using the quan-
tile normalization method according to the manufacturer’s
recommendation. The probes were considered as expressed
by filtering data on Detection p-value lower than 0.05. Data
are presented as the ratio of the average values ob-
tained from 2 separate pools of Matrigels retrieved from
3 DUSP3−/− mice on 2 separate pools of Matrigels re-
trieved from 3 DUSP3+/+ mice and the corresponding
p-value was determined using unpaired student’s t test. A
value of p < 0.05 was considered as statistically significant.
Statistical analysis
The student t-test was used to assess statistical differences be-
tween different groups. Results were considered as significant
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Prism software (GraphPad, San Diego, CA) was used to
perform statistical analysis. * = p < 0.05, ** = p < 0.01, ***
= p < 0.001.
Additional files
Additional file 1: DUSP3 downregulation affects HUVEC cells
angiogenic sprouting. 72 hours after transfection with siCTL, HUVECs
were trypsinized and 7.5 × 103 from each transfection condition were
seeded on Matrigel solidified matrix in Lab-Tek chamber slides. Chambers
were immediately transferred to the stage of a Nikon A1R microscope
and maintained for 16 hours at 37°C and 5% CO2 culture conditions.
Images were acquired every 10 minutes using Nis Elements software and
saved as ND2 files. Individual files were then combined and processed
into AVI. Representative movie for siCTL (movie 1) condition are shown.
Additional file 2: DUSP3 downregulation affects HUVEC cells
angiogenic sprouting. 72 hours after transfection with siDUSP3-1, HUVECs
were trypsinized and 7.5 × 103 from each transfection condition were
seeded on Matrigel solidified matrix in Lab-Tek chamber slides. Chambers
were immediately transferred to the stage of a Nikon A1R microscope and
maintained for 16 hours at 37°C and 5% CO2 culture conditions. Images
were acquired every 10 minutes using Nis Elements software and saved as
ND2 files. Individual files were then combined and processed into AVI.
Representative movie for siDUSP3 (movie 2) condition are shown.
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